Clinical trials: Blood
NAFLD, NASH - Nonalcoholic Steatohepatitis
Vitamin E for NASH Treatment in HIV Infected Individuals
The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
- Trial name
- NCT03669133
- Testing
- Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
HIV Infections, HIV-1
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen…
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Trial name
- NCT00540449
- Testing
- TMC278, Efavirenz
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 694 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis B
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
The investigators evaluated the safety and efficacy of a short lead-in course (8 weeks) of entecavir followed by combination of entecavir plus peginterferon alfa-2a for 40 weeks.
- Trial name
- HBRN (NCT01369199)
- Testing
- Entecavir and peginterferon
- Where
- 21 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infections, Fatigue
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
This study will determine whether armodafinil (Nuvigil), an FDA approved medication, is effective in reducing fatigue in adults with HIV/AIDS.
- Trial name
- NCT00737204
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- New York State Psychiatric Institute
Relapsed Refractory Multiple Myeloma
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
To characterize safety associated with the use of Kyprolis under the locally approved label.
- Trial name
- NCT03934684
- Testing
- Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone
- Where
- 17 sites in India
- Volunteers
- 101 people
- Sponsor
- Amgen
Major Depressive Disorder
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
This study will compare the effect of three transcranial photobiomodulation (t-PBM) doses (high, middle, and low irradiance) to sham t-PBM on PFC CBF as assessed with fMRI (BOLD) in this multi-center, phase I, double-blinded…
- Trial name
- TRIADE (NCT04366258)
- Testing
- Transcranial Photobiomodulator
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Venous Thromboembolism, Secondary Prevention
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients.
- Trial name
- NCT02197416
- Testing
- dabigatran etexilate
- Where
- 62 sites in United States, Austria and 20 more
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
HIV Coinfection
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
- Trial name
- NCT01327547
- Testing
- Maraviroc
- Where
- 48 sites in United States, Czechia and 7 more
- Volunteers
- 138 people
- Sponsor
- ViiV Healthcare
Immunodeficiency Virus Type 1, Human
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC…
- Trial name
- NCT02431247
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC
- Where
- 80 sites in United States, Belgium and 8 more
- Volunteers
- 725 people
- Sponsor
- Janssen Sciences Ireland UC
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thrombocytopenia
Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
This study is to evaluate the safety of intravenous (IV) infusion of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP) in participants with World Health Organization (WHO) Grade 2 bleed in spite of receiving a transfusion…
- Trial name
- NCT02078284
- Testing
- CPP, LSP
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- U.S. Army Medical Research and Development Command
Von Willebrand Disease
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.
- Trial name
- NCT00555555
- Testing
- Alphanate SD/HT
- Volunteers
- 4 people
- Sponsor
- Grifols Biologicals, LLC
Severe Hemophilia A
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
The primary objective of the study is to compare the pharmacokinetic (PK) of recombinant coagulation factor VIII Fc fusion protein (rFVIIIFc) manufactured at the current scale of 2000 L (2K) to the PK of rFVIIIFc manufactured at…
- Trial name
- Elevate (NCT02502149)
- Testing
- rFVIIIFc
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Bioverativ Therapeutics Inc.
Hypertension, Cardiovascular Disease
Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension
Angiotensin Therapeutic Vaccine (ATV), which contains the novel adjuvant, CoVaccine HT™ , is being developed for the treatment of high blood pressure (hypertension), a major risk factor for serious diseases such as heart attacks…
- Trial name
- NCT00702221
- Testing
- Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant, CoVaccine HT™ adjuvant
- Where
- 12 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- BTG International Inc.
Blood Coagulation Tests
Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay
Central Neuraxial Blockade (CNB) is commonly used in anaesthetics. It has several advantages over a general anaesthetic however contraindications include coagulopathy.
- Trial name
- NCT02255214
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- NHS Lothian
HIV Infections
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir.
- Trial name
- NCT03016533
- Testing
- Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets
- Where
- 17 sites in United States, Botswana and 5 more
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus, Depression
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
The purpose of this study is to test the efficacy of Our Family Our Future, an integrated intervention for preventing HIV and depression onset among adolescents.
- Conditions
- Human Immunodeficiency Virus, Depression, Sexually Transmitted Diseases
- Trial name
- NCT03231358
- Testing
- Our Family Our Future
- Where
- South Africa
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- Brown University
Brain Neoplasms, Surgery
Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy
Few studies look into cerebral blood flow (CBF) changes during emergence from general anesthesia for craniotomy. The purpose of this study is to demonstrate CBF changes during emergence from general anesthesia for craniotomy…
- Conditions
- Brain Neoplasms, Surgery, Hyperemia
- Trial name
- NCT01642147
- Testing
- Transcranial Doppler (TCD), jugular venous bulb catheterization, Tumor removal surgery under general anesthesia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
HIV/AIDS
A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans
Project Rise is a randomized controlled trial (RCT) of an innovative, culturally congruent treatment education (TE) intervention for African Americans with HIV that targets cultural and social issues contributing to health…
- Trial name
- NCT03331978
- Testing
- Rise - Treatment Education
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- RAND
Hemophilia B
A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
This study will examine the safety and efficacy of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) for the control and prevention of bleeding episodes in subjects who have previously received factor…
- Trial name
- NCT01361126
- Testing
- Recombinant Coagulation Factor IX Albumin Fusion Protein
- Where
- 2 sites in Bulgaria, Israel
- Volunteers
- 17 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.